Nanoparticle-Delivered Apoptosis Peptide Reduces Tumor Growth 85% When Combined with Chemotherapy
A cell-penetrating peptide carrying an apoptosis trigger, delivered via nanoparticles, reduced tumor growth by 85% when combined with doxorubicin chemotherapy in mice.
Quick Facts
What This Study Found
Smac-CPP nanoparticles combined with doxorubicin reduced tumor growth by 85% in vivo, with decreased Ki-67 proliferation staining and increased cleaved caspase-3 apoptosis staining in tumors.
Key Numbers
85% tumor growth reduction; 8-mer Smac + 14-mer CPP; decreased Ki-67, increased cleaved caspase-3
How They Did This
Synthesized chimeric Smac-CPP peptide (8-mer Smac + 14-mer CPP), encapsulated in PLGA nanoparticles. In vitro testing in 4T1 mammary tumor cells for uptake, viability, and caspase activation. In vivo combination therapy with doxorubicin in mouse breast cancer model.
Why This Research Matters
Cancer cells often resist apoptosis, limiting chemotherapy effectiveness. Delivering apoptosis-triggering peptides directly into tumor cells could sensitize them to standard chemotherapy drugs.
The Bigger Picture
This nanoparticle-peptide approach addresses multiple challenges simultaneously: peptide stability, intracellular delivery, and chemotherapy resistance. It represents a growing trend of combining peptide therapeutics with nanotechnology for cancer treatment.
What This Study Doesn't Tell Us
Mouse model only with unspecified group sizes. PLGA nanoparticle manufacturing scalability not addressed. Long-term toxicity and biodistribution not reported. Only tested with one chemotherapy drug.
Questions This Raises
- ?What is the optimal ratio of Smac-CPP-NPs to doxorubicin for maximum anti-tumor effect?
- ?Do the nanoparticles accumulate in off-target organs, and what are the systemic side effects?
- ?Could this approach work with other chemotherapy drugs or immunotherapies?
Trust & Context
- Key Stat:
- 85% tumor reduction Combination of Smac-CPP nanoparticles with doxorubicin achieved 85% tumor growth inhibition in mice
- Evidence Grade:
- Preliminary — promising mouse model results with a single tumor type; no human data or long-term safety assessment.
- Study Age:
- Published in 2020; nanoparticle-peptide combination therapies remain an active area of preclinical cancer research.
- Original Title:
- Apoptosis-inducing peptide loaded in PLGA nanoparticles induces anti-tumor effects in vivo.
- Published In:
- International journal of pharmaceutics, 585, 119535 (2020)
- Authors:
- Priwitaningrum, Dwi L, Jentsch, Julian, Bansal, Ruchi, Rahimian, Sima, Storm, Gert, Hennink, Wim E, Prakash, Jai
- Database ID:
- RPEP-05076
Evidence Hierarchy
Tests effects in animals (usually mice or rats), not humans.
What do these levels mean? →Frequently Asked Questions
What is Smac and how does it kill cancer cells?
Smac is a naturally occurring protein that promotes apoptosis (programmed cell death) by blocking proteins that protect cancer cells from dying. The Smac mimetic peptide activates this same pathway, making cancer cells vulnerable to death signals.
Why use nanoparticles to deliver the peptide?
Peptides break down quickly in the body and struggle to enter cells on their own. PLGA nanoparticles protect the peptide, deliver it to tumors through passive targeting, and release it inside cancer cells for maximum effect.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-05076APA
Priwitaningrum, Dwi L; Jentsch, Julian; Bansal, Ruchi; Rahimian, Sima; Storm, Gert; Hennink, Wim E; Prakash, Jai. (2020). Apoptosis-inducing peptide loaded in PLGA nanoparticles induces anti-tumor effects in vivo.. International journal of pharmaceutics, 585, 119535. https://doi.org/10.1016/j.ijpharm.2020.119535
MLA
Priwitaningrum, Dwi L, et al. "Apoptosis-inducing peptide loaded in PLGA nanoparticles induces anti-tumor effects in vivo.." International journal of pharmaceutics, 2020. https://doi.org/10.1016/j.ijpharm.2020.119535
RethinkPeptides
RethinkPeptides Research Database. "Apoptosis-inducing peptide loaded in PLGA nanoparticles indu..." RPEP-05076. Retrieved from https://rethinkpeptides.com/research/priwitaningrum-2020-apoptosisinducing-peptide-loaded-in
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.